Encinitas, CA, United States of America

Robert Owen Sayers



Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2011

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Robert Owen Sayers

Introduction

Robert Owen Sayers is a notable inventor based in Encinitas, California, known for his innovative work in the field of biotechnology. He has made significant contributions to the medical industry through his research and development of monoclonal antibodies. With a keen focus on muscle growth and bone health, Sayers has secured one patent that showcases his commitment to advancing scientific knowledge.

Latest Patents

Sayers holds a patent for "Anti-myostatin antibodies," which highlights the development of monoclonal antibodies that preferentially bind to myostatin over GDF-11. These antibodies are characterized by their strong binding affinity to myostatin, making them resistant to chemical degradation. The innovative antibodies are pivotal for increasing muscle mass and bone density, and they offer potential treatment options for a variety of disorders in both mammalian and avian species.

Career Highlights

Robert Owen Sayers is currently affiliated with Eli Lilly and Company, a well-respected corporation in the pharmaceutical industry. His role involves leveraging his expertise in antibody development to contribute to the company's research initiatives. Notably, his work not only advances product development but also plays a crucial role in enhancing patient care through innovative therapies.

Collaborations

In his professional journey, Sayers has collaborated with another skilled researcher, Lihua Huang. Their partnership exemplifies the synergy that can arise from combining diverse expertise and perspectives in scientific research. Together, they contribute to the advancement of biopharmaceutical innovations that can have a lasting impact on healthcare.

Conclusion

Robert Owen Sayers stands out as an inventive force within the biotechnology sector. His patent on anti-myostatin antibodies underscores his commitment to improving health outcomes and promoting innovative solutions in medicine. Through his work at Eli Lilly and Company and his collaborations with other researchers, Sayers continues to pave the way for novel therapeutics that address crucial health issues.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…